Sotagliflozin FDA：Inpefa (sotagliflozin) tablets

Inpefa (sotagliflozin) tablets

2023年5月26日—forInpefa(sotagliflozin)tablets.ThisNDAprovidesfortheuseof...FormFDA2253isavailableatFDA.gov.4.InformationandInstructions ...。其他文章還包含有：「DualSGLT1andSGLT2inhibitorsotagliflozinachieves...」、「FDAApprovesSotagliflozinforTreatmentofHeartFailure」、「FDAApprovesSotagliflozin」、「FDAUpdate」、「Inpefa(sotagliflozin)FDAApprovalHistory」、「INPEFATM(sotagliflozin)tablets」...

查看更多離開網站

Provide From Google

Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves ...

https://www.nature.com

The FDA has approved sotagliflozin for the reduction of major heart-failure events in patients with and or diabetes, an indication that closely ...

Provide From Google

FDA Approves Sotagliflozin for Treatment of Heart Failure

https://www.hcplive.com

The FDA approval of sotagliflozin (Inpefa) for the treatment of heart failure was announced by Lexicon Pharmaceuticals on May 26, 2023.

Provide From Google

FDA Approves Sotagliflozin

https://www.ajmc.com

The FDA late Friday approved sotagliflozin, the first dual sodium-glucose cotransporter 1 and 2 (SGLT1/2) inhibitor, for the treatment of ...

Provide From Google

FDA Update

https://www.acc.org

The once-daily oral tablet is approved to reduce the risk of cardiovascular death, hospitalization for HF, and urgent HF visits in adult ...

Provide From Google

Inpefa (sotagliflozin) FDA Approval History

https://www.drugs.com

Inpefa (sotagliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the treatment of heart failure.

Provide From Google

INPEFATM (sotagliflozin) tablets

https://www.accessdata.fda.gov

See 17 for PATIENT COUNSELING INFORMATION and. FDA-approved Medication Guide. Revised: 05/2023. FULL PRESCRIBING INFORMATION: CONTENTS*. 1 INDICATIONS AND USAGE.

Provide From Google